



# **Technical Report No. 89**

## Strategies for Vaccine Development and Lifecycle Management



## Strategies for Vaccine Development and Lifecycle Management

---

### Authors and Contributors

---

**Sabrina Restrepo**, PhD, Merck & Co.  
(Co-Chair)

**Jane Halpern**, PhD, IAVI (Co-Chair)

**Mihai Bilanin**, PhD, GSK Vaccines

**Cristiana Campa**, PhD, GSK Vaccines

**Clarice Hutchens**, PhD, Pfizer Inc.

**Mahesh Krishnan**, PhD, Merck & Co.

**Lyne Le Paire**, Sanofi Pasteur

**Mic McGoldrick**, Merck & Co.

**Priyabrata Pattnaik**, PhD, Indian Immunologicals Limited

**Richard Pelt**, Pfizer Inc.

**Jon Shanter**, Merck & Co.

# Strategies for Vaccine Development and Lifecycle Management

**Technical Report No. 89**

ISBN: 978-1-945584-37-4

© 2023 Parenteral Drug Association, Inc.

All rights reserved.



# Table of Contents

<b>1.0 INTRODUCTION</b> .....	<b>1</b>	5.2 Challenges of Using Comparability Assessments for Vaccines .....	13
1.1 Purpose .....	2	5.3 Recommended Considerations for Comparability Protocols and Comparability Assessments for Vaccines .....	14
1.2 Scope .....	3	5.4 Suggested Best Practices for Comparability Assessments.....	16
<b>2.0 ABBREVIATIONS</b> .....	<b>4</b>		
<b>3.0 EXISTING GUIDANCE DOCUMENTS FOR VACCINES...</b>	<b>4</b>		
<b>4.0 CONTROL STRATEGY FROM PROCESS DEVELOPMENT TO VACCINE LIFECYCLE MANAGEMENT</b> .....	<b>6</b>	<b>6.0 CONSIDERATIONS FOR VACCINES LIFECYCLE MANAGEMENT</b> .....	<b>19</b>
4.1 Key Elements and Considerations for Establishing Vaccines Control Strategy.....	6	6.1 Nonregulatory Considerations for Management of Post-Approval Changes .....	20
4.2 Considerations for Setting and Managing Vaccine Specifications .....	7	6.1.1 Technical Considerations for Management of Changes .....	20
4.2.1 Considerations for Setting Vaccine Specifications: Critical Quality Attributes and Ranges .....	7	6.1.2 Validation Considerations for Management of Changes .....	26
4.2.2 Approaches for Analytical Procedures Selection in Specifications .....	9	6.1.3 Relying on Effective Pharmaceutical Quality System for Management of Changes.....	29
4.2.3 Managing Vaccine Specifications throughout Product Lifecycle.....	10	6.1.4 Use of a Risk-Based Approach and Development of an Effective PQS.....	29
4.3 Establishing Process Parameter Classifications and Lifecycle Management .....	10	6.2 Regulatory Considerations for Management of Post-Approval Changes .....	30
4.3.1 Considerations for Establishing Process Parameter Classifications.....	10	6.2.1 General Regulatory Considerations for Management of PACs.....	31
4.3.2 Considerations for Reclassification of Parameters .....	11	6.2.2 Key Considerations for Post-Approval Change Submissions.....	32
<b>5.0 COMPARABILITY ASSESSMENTS: ENABLER FOR CHANGES DURING DEVELOPMENT AND AFTER APPROVAL</b> .....	<b>12</b>	6.2.3 Using the Regulatory Mechanism of ICH Q12.....	33
5.1 Benefits of Comparability Protocols and Comparability Exercises for Vaccines.....	12	6.2.4 Strategies for Multinational and Multiproduct Submissions .....	36
		<b>7.0 CONCLUSION</b> .....	<b>37</b>
		<b>8.0 REFERENCES</b> .....	<b>38</b>

## FIGURES AND TABLES INDEX

<b>Figure 1.0-1</b> Complexity of Vaccine Development and Lifecycle Management.....	1	<b>Table 5.2-1</b> Examples where Vaccine Changes Could be Justified with Analytical or Target Clinical Data .....	14
<b>Table 1.0-1</b> Diversity in Vaccine Platforms .....	2	<b>Table 5.3-1</b> Examples of Quality Attributes that Could Leverage Analytical Comparability.....	15
<b>Table 3.0-1</b> Summary of Selected Guidance and Industry Documents and Relevance to Strategies for Vaccines Development and Lifecycle Management .....	5	<b>Table 5.3-2</b> Examples where Comparability could be Considered without Need for Additional Clinical Studies.....	15
<b>Figure 4.1-1</b> Holistic Control Strategy for Vaccines Development and Lifecycle .....	6	<b>Table 5.3-3</b> Examples when Clinical Data may be Required to Support Comparability.....	16
<b>Table 4.2.1-1</b> Examples of Quality Attributes with Additional Considerations for Vaccines.....	8	<b>Table 5.4-1</b> Practical Considerations for Comparability Assessments .....	16
<b>Table 4.3.2-1</b> Examples of Parameter Classification Changes .....	11	<b>Figure 5.4-2</b> Timing of Implementation Using	

	Comparability Protocol .....	18	<b>Table 6.1.2.3-1</b>	Matrix Approach using Three Strategies .....	27
<b>Table 5.4-2</b>	Common Comparability Protocols Received by U.S. FDA, 2004-2014.....	18	<b>Figure 6.1.2.3-1</b>	Representation of Matrix Validation Approach .....	28
<b>Figure 6.0-1</b>	Representation of the Complexity in Managing Multinational Regulatory Submissions.....	19	<b>Table 6.1.2.3-2</b>	Illustration of a Matrix Approach for Filling Process PPQ .....	28
<b>Figure 6.0-2</b>	Vaccine Inventory Complexity Management .....	20	<b>Figure 6.1.4-1</b>	Risk-Based Assessment of PACs and Determination of Regulatory Reporting Category .....	30
<b>Figure 6.1-1</b>	Vaccine Lifecycle Management Complexity.....	21	<b>Table 6.2.1-1</b>	Overview of the Current Situation and Proposals for Improvement.....	32
<b>Table 6.1.1.2-1</b>	Examples of Working Cell Bank Manufacturing Changes, Potential Classification, and Supporting Data Expectations .....	23	<b>Figure 7.0-1</b>	Key Elements to Consider during Development of a Vaccine Strategy.....	38


# 1.0 Introduction

Vaccines comprise a very diverse group of products with respect to chemical composition and manufacturing processes. Vaccines can also be very complex as they are frequently composed of multiple entities and administered as a combination vaccine. For instance, six or more different antigens can be included in common pediatric vaccines, and seasonal influenza vaccines are quadrivalent. Adding to that complexity, many vaccines are administered with adjuvants that may involve complex formulations and manufacturing processes. The use of adjuvants increases the challenges of developing a robust control strategy.

Vaccines are characterized by relatively long product lifecycles. Vaccines that were licensed decades ago (e.g., for tetanus and diphtheria toxoids, tuberculosis, measles, mumps, and rubella) are still produced and recommended for global vaccination programs. The manufacturing programs for these vaccines must be updated continually to comply with contemporary regulatory expectations, which requires multiple supplemental submissions around the world. These technical and regulatory challenges lead to an intricate management process for vaccine lifecycle and supply chain.

Managing the development, licensure, and lifecycle of vaccines is an extremely complicated process, especially in cases of multinational products. **Figure 1.0-1** illustrates the complexities of vaccine development and commercialization; many of these are common to other biological products.

For most vaccine platforms, developing and launching vaccines can take several years. After a vaccine becomes commercially available, it can take from 6–36 months to produce, control, and release a batch. The majority of this time may be spent on product testing and release. From bulk antigen production through product release, the entire process must be strictly controlled to ensure sterility and to minimize the variability inherent in a biological system. Up to 1,000 control tests may be performed during the manufacturing cycle for each lot of vaccine, including complex in-vivo tests. Additional testing required by national health authority laboratories adds to the intricacy of releasing a vaccine in local markets, though many health authorities are willing to conduct testing in parallel with the manufacturer to minimize the time-delay associated with official control batch-release testing.



**Figure 1.0-1** Complexity of Vaccine Development and Lifecycle Management